Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKAG1 | P54619 | 15/20 | 0.52 |
| ▸ | PRKAA1 | Q13131 | 15/20 | 0.52 |
| ▸ | PRKAB1 | Q9Y478 | 15/20 | 0.52 |
| ▸ | HAO1 | Q9UJM8 | 2/20 | 0.51 |
| ▸ | PRKAB2 | O43741 | 14/20 | 0.43 |
| ▸ | PRKAA2 | P54646 | 14/20 | 0.43 |
| ▸ | PRKAG3 | Q9UGI9 | 14/20 | 0.43 |
| ▸ | PRKAG2 | Q9UGJ0 | 14/20 | 0.43 |
| ▸ | KIF11 | P52732 | 1/20 | 0.42 |
| ▸ | TTK | P33981 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL492005 | 0.87 | TTK (0.49) | PRKAG1PRKAA1PRKAB1HAO1PRKAB2 | |
| SCHEMBL4436081 | 0.82 | KDM4E (0.60) | PRKAG1PRKAA1PRKAB1KIF11 | |
| SCHEMBL9909089 | 0.81 | PRKAG1 (0.39) | PRKAG1PRKAA1PRKAB1HAO1KIF11 | |
| SCHEMBL6526757 | 0.80 | JAK2 (0.55) | KIF11TTK | |
| SCHEMBL1963000 | 0.79 | KDM4E (0.43) | PRKAG1PRKAA1PRKAB1KIF11 | |
| SCHEMBL14792020 | 0.78 | PRKAG1 (0.56) | PRKAG1PRKAA1PRKAB1HAO1PRKAB2 | |
| SCHEMBL1963463 | 0.78 | PRKAG1 (0.56) | PRKAG1PRKAA1PRKAB1HAO1PRKAB2 | |
| SCHEMBL4008217 | 0.78 | PRKAG1 (0.56) | PRKAG1PRKAA1PRKAB1HAO1PRKAB2 | |
| SCHEMBL4429972 | 0.78 | PRKAA1 (0.41) | PRKAG1PRKAA1PRKAB1KIF11TTK | |
| SCHEMBL260615 | 0.77 | PDPK1 (0.61) | PRKAG1PRKAA1PRKAB1HAO1PRKAB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130217683-A1 | INDAZOLES, BENZOTHIAZOLES, BENZOISOTHIAZOLES, BENZISOXAZOLES, AND PREPARATION AND USE THEREOF | MEMORY PHARMACEUTICALS CORPORATION (US) | 2013-08-22 | — | — | US | disclosed |
| US-8486937-B2 | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and use thereof | MEMORY PHARMACEUTICALS CORPORATION (US) | 2013-07-16 | — | — | US | disclosed |
| US-8263619-B2 | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof | MEMORY PHARMACEUTICALS CORPORATION (US) | 2012-09-11 | — | — | US | disclosed |
| US-20110319407-A1 | INDAZOLES, BENZOTHIAZOLES, BENZOISOTHIAZOLES, BENZISOXAZOLES, AND PREPARATION AND USE THEREOF | XIE WENGE (US) | 2011-12-29 | — | — | US | disclosed |
| EP-2336128-A1 | Benzoisothiazoles and preparation and uses thereof | Memory Pharmaceuticals Corporation (US) | 2011-06-22 | — | — | EP | disclosed |
| US-20100105677-A1 | INDAZOLES, BENZOTHIAZOLES, BENZOISOTHIAZOLES, BENZISOXAZOLES, AND PREPARATION AND USES THEREOF | XIE WENGE | 2010-04-29 | — | — | US | disclosed |
| EP-1735306-A2 | INDAZOLES, BENZOTHIAZOLES, BENZOISOTHIAZOLES, BENZISOXAZOLES, AND PREPARATION AND USES THEREOF | Memory Pharmaceuticals Corporation (US) | 2006-12-27 | — | — | EP | disclosed |
| US-20050234095-A1 | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof | MEMORY PHARMACEUTICALS CORPORATION | 2005-10-20 | — | — | US | disclosed |
| WO-2005092890-A2 | INDAZOLES, BENZOTHIAZOLES, BENZOISOTHIAZOLES, BENZISOXAZOLES, AND PREPARATION AND USES THEREOF | MEMORY PHARMACEUTICALS CORPORATION (US) | 2005-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319407-A1 | INDAZOLES, BENZOTHIAZOLES, BENZOISOTHIAZOLES, BENZISOXAZOLES, AND PREPARATION AND USE THEREOF | CHRNA7, CHRNA5, CHRNA3 | PRKAG1 1882/4885PRKAA1 1894/4885PRKAB1 2165/4885 |
| US-20100105677-A1 | INDAZOLES, BENZOTHIAZOLES, BENZOISOTHIAZOLES, BENZISOXAZOLES, AND PREPARATION AND USES THEREOF | CHRNA7, CHRNA5, CHRNA3 | PRKAG1 1796/4885PRKAA1 1849/4885PRKAB1 2098/4885 |
| US-20130217683-A1 | INDAZOLES, BENZOTHIAZOLES, BENZOISOTHIAZOLES, BENZISOXAZOLES, AND PREPARATION AND USE THEREOF | CHRNA7, CHRNA5, CHRNA3 | PRKAG1 1882/4885PRKAA1 1894/4885PRKAB1 2165/4885 |
| US-20050234095-A1 | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof | CHRNA7, CHRNA5, CHRNA3 | PRKAG1 1796/4885PRKAA1 1849/4885PRKAB1 2098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.